@article{article, title  = {{Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.}},

 publisher = {{NIHR Health Technology Assessment Programme}},

 url = {{https://eprints.whiterose.ac.uk/id/eprint/100350 http://dx.doi.org/10.3310/hta20390 }},

 year = {{2016}},

 month = {{5}},

 author = {{Archer R and Tappenden P and Ren S and Martyn-St James M and Harvey R and Basarir H and Stevens J and Carroll C and Cantrell A and Lobo A and Hoque S}},

 doi = {{10.3310/hta20390}},

 volume = {{20}},

 journal = {{Health Technoogyl Assessment}},

 note = {{Accessed on 2025/10/31}}}